A multimodal viro-immunotherapy strategy for glioblastoma
Abstract
In our recent study published in Nature Communications, we developed a multimodal immunotherapy strategy for glioblastoma (GBM), the most malignant primary brain tumor, that integrates engineered immune cells with complementary oncolytic virus platforms.1 GBM remains one of the most challenging solid tumors to treat because tumor heterogeneity and a profoundly immunosuppressive tumor microenvironment limit the durability of currently available treatment options.2,3 These same features constrain the effectiveness of CAR-based immunotherapy for GBM, where incomplete target coverage, antigen escape, and poor persistence of transferred immune cells can all reduce therapeutic benefit.
Fields of Study & Subjects
Glioma Diagnosis and Treatment
Virus-based gene therapy research
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Molecular Therapy Oncology
- Publisher
- Elsevier BV
- Volume
- 34
- Issue
- 2
- Pages
- 201233–201233
- Publication date
- 23 May 2026
- Language
- EN